Gilead Sciences Aktie
| 88,62USD | 0,89USD | 1,01% |
WKN: 885823 / ISIN: US3755581036
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,90 |
| The Vanguard Group, Inc. | 8,98 |
| Vanguard Group, Inc. (Subfiler) | 8,80 |
| Capital Research & Management Co. (World Investors) | 6,72 |
| Capital Research & Management Co. (World Investors) | 6,15 |
| Capital Research & Management Co. (Global Investors) | 4,96 |
| State Street Corp. | 4,83 |
| BlackRock Fund Advisors | 3,82 |
| Vanguard Total Stock Market ETF | 3,17 |
| Dodge & Cox | 2,65 |
| Wellington Management Co. LLP (Wellington Breakout) | 2,64 |
| Vanguard 500 Index Fund | 2,62 |
| American Funds Income Fund of America | 2,50 |
| BlackRock Institutional Trust Co. NA | 2,30 |
| Geode Capital Management LLC | 2,21 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 11 800 | 13 600 | 14 400 | 17 000 | 18 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,89 | 1,81 | 1,90 | 1,59 | 1,50 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 30 296 | 15 996 | 14 772 | 14 443 | 16 085 |
| Summe Anlagevermögen | 31 331 | 52 411 | 53 180 | 48 728 | 46 040 |
| Summe Aktiva | 61 627 | 68 407 | 67 952 | 63 171 | 62 125 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 25 318 | 32 117 | 27 285 | 25 230 | 25 658 |
| Summe Fremdkapital | 38 977 | 50 186 | 46 888 | 41 962 | 39 376 |
| Summe Eigenkapital | 22 650 | 18 221 | 21 064 | 21 209 | 22 749 |
| Summe Passiva | 61 627 | 68 407 | 67 952 | 63 171 | 62 125 |
Adresse
| 333 Lakeside Drive, 94404 Foster City | |
| Telefon | +1 (650) 574-3000 |
| Fax | +1 (650) 522-5853 |
| Internet | http://www.gilead.com |
Management
|
Adam D. Levy
Executive Director-Investor Relations |
|
Andrew D. Dickinson
Chief Financial Officer |
|
Anthony Welters
Independent Director |
|
Cindy Perettie
Executive Vice President-Kite |
|
Daniel P. O'Day
Chairman & Chief Executive Officer |
|
Deborah H. Telman
Secretary, EVP-Corporate Affairs & General Counsel |
|
Dustin Haines
Vice President & General Manager-Asia 5 |
|
Flavius Martin
Executive Vice President-Research |
|
Harish M. Manwani
Independent Director |
|
Jacqueline K. Barton
Independent Director |
|
Jacquie Ross
Head-Investor Relations |
|
Janet Dorling
Senior VP- Intercontinental Region |
|
Javier J. Rodriguez
Independent Director |
|
Jeffrey A. Bluestone
Independent Director |
|
Johanna Mercier
Chief Commercial Officer |
|
Joydeep Ganguly
Senior Vice President-Corporate Operations |
|
Jyoti K. Mehra
Executive Vice President-Human Resources |
|
Kelly A. Kramer
Independent Director |
|
Linda Slanec Higgins
Senior VP-Research & External Innovation |
|
Melissa Grigorieff Koomey
Vice President-Global Commercial Operations |
|
Merdad V. Parsey
Chief Medical Officer |
|
Robert D. Cook
Vice President |
|
Sandra J. Horning
Independent Director |
|
Sandra K. Patterson
SVP, Chief Accounting Officer & Controller |
|
Sarah C. Pope Miksinski
Executive Director-CMC Regulatory Affairs |
|
Stacey Y. Ma
EVP-Pharmaceutical Development & Manufacturing |
|
Ted W. Love
Independent Director |
|
Tomas Cihlar
Vice President-Virology |
|
William Grossman
Senior VP-Oncology Clinical Development |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
